Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Energy Save - Cool Q2 ahead, but H2'25e set to heat up

19 maj 2025

<a id="bm-comp-6e9a8d46-ccef-4bf2-b1cc-fa1defba94ee" name="bm-comp-6e9a8d46-ccef-4bf2-b1cc-fa1defba94ee" class="BMCustomAnchor"></a><table><tr><td bm-component-id="6e9a8d46-ccef-4bf2-b1cc-fa1defba94ee" style="vertical-align: top; width:100.000000%;"><ul><li>Q1 sales +40% y-o-y, +2% q-o-q, FCF negative</li><li>Cut '25e-'27e sales by 7% on weaker Q2 outlook</li><li>Market recovery and new products to support H2'25e</li></ul></td></tr></table><a id="bm-comp-a19a6f0a-5d15-4454-b5b9-dacbf5fa8936" name="bm-comp-a19a6f0a-5d15-4454-b5b9-dacbf5fa8936" class="BMCustomAnchor"></a><table><tr><td bm-component-id="a19a6f0a-5d15-4454-b5b9-dacbf5fa8936" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">New products and distributors to support H2'25e</h3><p>Energy Save reported Q1 sales of SEK 54m (+40% y-o-y, +2% q-o-q). EBIT was higher than expected at SEK -4m (vs. ABGSCe -7m) due to the company's newly implemented cost-cutting programme. We expect Q2 to be a weaker quarter (-31% q-o-q), due to inventory buildup among OEM customers, but we anticipate an upturn in H2'25e (est. ~40% y-o-y growth in H2'25e), driven by normalising inventory levels and a gradual market recovery. We expect higher volumes in H2'25e to drive EBIT growth, with positive margins and FCF anticipated in '26e. The company&#8217;s ~SEK 30m cash balance should provide sufficient support until then. Growth continues to be underpinned by the Aira partnership (we estimate revenues of ~SEK 200m for '25e). However, we expect both ES-branded sales and Commercial to gradually improve towards H2'25e with the help of the company's new product launches.</p><h3 class="bm-h3">Lower '25e-'27e sales amid soft Q2 outlook</h3><p>Due to the company's weak Q2 outlook, we lower '25e-'27e sales by 7%, but only lower '25e-'27e EBIT by 6-4% due to the company's increased focus on cost control.</p><h3 class="bm-h3">Waiting for the market recovery</h3><p>Although the company has recently invested in growth and has established more partnerships with new distributors, we believe that the main long-term driver for both volumes and profitability remains improving market conditions. We expect these conditions to gradually improve in H2'25e, supporting higher volumes for ES outside the Aira partnership and enabling the company to achieve positive EBIT by '26e. The company is currently trading at 0.4x-0.2x EV/Sales '25e-'27e and 5x-2x EV/EBIT '26e-'27e, ~50-90% below cleantech and HVAC peers. We maintain our fair value range of SEK 25-76.</p></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-02-12 Infrea - Cleaning the pipes for future performance Infrea Analys
2026-02-12 INVISIO - Better-than-expected on all items INVISIO Analys
2026-02-12 Fastpartner - Steep cut to run-rate IFPM Fastpartner Analys
2026-02-12 Clavister - Clavister continues to scale Clavister Analys
2026-02-12 OrganoClick - Positive sales in binders, weak els... OrganoClick Analys
2026-02-12 Nilörn - Strong orders, but pressured margins Nilörn Analys
2026-02-12 Ferronordic - Strong U.S. more than offsets Germany Ferronordic Analys
2026-02-12 NYAB - EBIT in line, organic growth remains good NYAB Analys
2026-02-12 Generic - Gross margins up but costs weigh in Q4 Generic Analys
2026-02-12 Coor - More margin improvements in 2026 Coor Analys
2026-02-11 Medicover - Path to 2028 explained Medicover Analys
2026-02-11 Careium - Bittersweet outlook on 2026 Careium Analys
2026-02-11 Catella - Divestment fuels stronger finish to the... Catella Analys
2026-02-11 Careium - Margin pressure to remain in H1'26 Careium Analys
2026-02-11 Prevas - Margins improving as volumes stabilise Prevas Analys
2026-02-11 Coor - Miss from Denmark, but proposes buybacks Coor Analys
2026-02-10 Medicover - A promising trajectory Medicover Analys
2026-02-10 Proact - Earnings resilience remains impressive Proact Analys
2026-02-10 Prevas - Stable quarter closing the year Prevas Analys
2026-02-10 Proact - Cost savings ahead of expectations Proact Analys